NCT05724329

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

Active, enrolled Phase 2 Last updated 19 September 2024

What this trial tests

Phase 2 trial testing Tislelizumab + Dasatinib + Quercetin (neoadjuvant) in Head and Neck Squamous Cell Carcinomas in 24 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

5 February 2023

Primary endpoint
5 April 2024

5 August 2028

Quick facts

Lead sponsor	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	5 February 2023
Primary completion	5 April 2024
Estimated completion	5 August 2028
Sites	1 location across China

Drugs / interventions tested

• Tislelizumab + Dasatinib + Quercetin (neoadjuvant) — full drug profile →
• surgery
• Tislelizumab + Dasatinib + Quercetin (adjuvant) — full drug profile →

Conditions studied

• Head and Neck Squamous Cell Carcinomas — all drugs for Head and Neck Squamous Cell Carcinomas →

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Who can join

Adults 18 to 80, any sex, with Head and Neck Squamous Cell Carcinomas. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The trial is being conducted to evaluate the efficacy and safety of Tislelizumab in combination with dasatinib and quercetin(combining immunotherapy and senolytics, COIS) in patients with head and neck squamous cell carcinoma who are about to undergo surgery.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Altered metabolism in cancer: insights into energy pathways and therapeutic targets.
   Tufail M, Jiang CH, Li N. · · 2024 · cited 265× · PMID 39294640 · DOI 10.1186/s12943-024-02119-3
2. Drug repurposing for cancer therapy.
   Xia Y, Sun M, Huang H, Jin WL. · · 2024 · cited 229× · PMID 38637540 · DOI 10.1038/s41392-024-01808-1
3. Oxidative Stress and Age-Related Tumors.
   Di Carlo E, Sorrentino C. · · 2024 · cited 33× · PMID 39334768 · DOI 10.3390/antiox13091109
4. RNA m6A modification in ferroptosis: implications for advancing tumor immunotherapy.
   Shi JX, Zhang ZC, Yin HZ, Piao XJ, et al · · 2024 · cited 29× · PMID 39342168 · DOI 10.1186/s12943-024-02132-6
5. Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy.
   Godiyal Y, Maheshwari D, Taniguchi H, Zinzuwadia SS, et al · · 2024 · cited 21× · PMID 39690423 · DOI 10.1186/s40779-024-00586-9
6. Age-related Changes in the Adrenal Cortex: Insights and Implications.
   Warde KM, Smith LJ, Basham KJ. · · 2023 · cited 14× · PMID 37564884 · DOI 10.1210/jendso/bvad097
7. Focal adhesion in the tumour metastasis: from molecular mechanisms to therapeutic targets.
   Liu Z, Zhang X, Ben T, Li M, et al · · 2025 · cited 12× · PMID 40045379 · DOI 10.1186/s40364-025-00745-7
8. Nature's weapons: Bioactive compounds as anti-cancer agents.
   Auti A, Tathode M, Marino MM, Vitiello A, et al · · 2024 · cited 11× · PMID 39416904 · DOI 10.3934/publichealth.2024038